Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › How it makes money
How NewAmsterdam Pharma Co N.V. (NAMS) makes money
NewAmsterdam Pharma Co N.V. (NAMS) made $19.2M of revenue in the third quarter 2026 (Q3 2026), up 55-fold from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $19.2M | 100.0% |
| Income tax | $1.2M | 6.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $19.2M | 55× |
| Q2 2026 | $3.7M | -81% |
| Q1 2026 | $3.0M | +2% |
| Q4 2025 | $32K | -100% |
| Q3 2025 | $348K | -99% |
| Q2 2025 | $19.1M | +740% |
| Q1 2025 | $3.0M | +113% |
From NewAmsterdam Pharma Co N.V.'s 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does NewAmsterdam Pharma Co N.V. make money?
NewAmsterdam Pharma Co N.V. (NAMS) made $19.2M of revenue in the third quarter 2026 (Q3 2026), up 55-fold from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.